NFA
BLCM

Nationwide Fund Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Nationwide Fund Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,553
Closed -$179K – 2378
2017
Q3 		$179K Hold
1,553
– – ﹤0.01% 2686
2017
Q2 		$181K Buy
1,553
+362
+30% +$44.9K ﹤0.01% 2666
2017
Q1 		$147K Sell
1,191
-156
-12% -$20.4K ﹤0.01% 2713
2016
Q4 		$183K Hold
1,347
– – ﹤0.01% 2643
2016
Q3 		$268K Hold
1,347
– – ﹤0.01% 2488
2016
Q2 		$175K Buy
1,347
+789
+141% +$87.8K ﹤0.01% 2674
2016
Q1 		$52K Sell
558
-500
-47% -$54.4K ﹤0.01% 2979
2015
Q4 		$214K Buy
1,058
+537
+103% +$96.1K ﹤0.01% 2514
2015
Q3 		$76K Sell
521
-35
-6% -$6.42K ﹤0.01% 2964
2015
Q2 		$118K Buy
556
+316
+132% +$77.5K ﹤0.01% 2971
2015
Q1 		$55K Buy
+240
New +$58.1K ﹤0.01% 3085

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nationwide Fund Advisors's BLCM Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2017, closing a stake of 1,553 shares — an estimated $179K sold.

Nationwide Fund Advisors first reported a position in BLCM in Q1 2015 and held it in 11 quarters. The position peaked at $268K in Q3 2016. 91 funds tracked by Wall St. Rank hold BLCM as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 1,553 Bellicum Pharmaceuticals, Inc. shares in Q4 2017, an estimated $179K.
  • Nationwide Fund Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
  • Nationwide Fund Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $268K in Q3 2016.
  • 91 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.